List of Triumeq drug patents

Triumeq is owned by Viiv Hlthcare.

Triumeq contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.

Triumeq has a total of 2 drug patents out of which 0 drug patents have expired.

Triumeq was authorised for market use on 22 August, 2014.

Triumeq is available in tablet;oral dosage forms.

The generics of Triumeq are possible to be released after 08 December, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 22 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TRIUMEQ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic